Strategic Advantage Target market expansion by highlighting RedPath's CLIA-certified and CAP-accredited lab, proven PathFinderTG platform, and cost-saving health economic studies to gastroenterologists, pathologists, and other physicians seeking reliable molecular diagnostics.

Clinical Evidence Leverage over 20 years of research and publishing footprint in 200+ peer-reviewed journals to build credibility with hospital systems and payers, supporting sales pitches with robust clinical data and Medicare/private payer coverage.

Cost Savings Emphasize demonstrated reductions in healthcare costs from recent economic studies to payer organizations and health systems, framing PathFinderTG as a value driver for diagnostic workflows and patient management.

Strategic Partners Position RedPath as a specialty molecular diagnostics partner for gastroenterology and pathology departments within mid to large healthcare networks that require niche, high-quality mutational profiling as part of cancer risk assessment.

Growth Readiness Highlight scalable capacity and FDA-regulated, research-informed testing capabilities suitable for expanding service offerings, potential collaborations, and integration with existing laboratory and EMR workflows.